Generic drug: tepotinib
Brand name: Tepmetko
What is Tepmetko (tepotinib), and how does it work?
Tepmetko (tepotinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:
- has spread to other parts of the body (metastatic), and
- whose tumors have an abnormal mesenchymal epithelial transition (MET) gene. Your healthcare provider will perform a test to make sure that Tepmetko is right for you.
It is not known if Tepmetko is safe and effective in children.
What are the side effects of Tepmetko?
Tepmetko may cause serious side effects, including:
- Liver problems.
Tepmetko may cause abnormal liver blood test results. Your healthcare provider will do blood tests to check your liver function before you start treatment and during treatment with
Tepmetko. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:
- your skin or the white part of your eyes turns yellow
- dark or “tea colored” urine
- light-colored stools (bowel movements)
- loss of appetite for several days or longer
- nausea and vomiting
- pain, aching, or tenderness on the right side of your stomach-area (abdomen)
- swelling in your stomach-area
The most common side effects of Tepmetko include:
- swelling in your face or other parts of your body
- muscle and joint pain
- shortness of breath
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Tepmetko if you develop serious side effects during treatment.
These are not all of the possible side effects of Tepmetko. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Tepmetko?
Patient Selection For METex14 Skipping Alterations
- Select patients for treatment with Tepmetko based on the presence of MET exon 14 skipping alterations in plasma or tumor specimens.
- Testing for the presence of MET exon 14 skipping alterations in plasma specimens is recommended only in patients for whom a tumor biopsy cannot be obtained.
- If an alteration is not detected in a plasma specimen, re-evaluate the feasibility of biopsy for tumor tissue testing.
- An FDA-approved test for detection of MET exon 14 skipping alterations in NSCLC for selecting patients for treatment with Tepmetko is not available.
- The recommended dosage of Tepmetko is 450 mg orally once dailywith food until disease progression or unacceptable toxicity.
- Instruct patients to take their dose of Tepmetko at approximately the same time every day and to swallow tablets whole. Do not chew, crush or split tablets.
- Advise patients not to make up a missed dose within 8 hours of the next scheduled dose. If vomiting occurs after taking a dose of Tepmetko, advise patients to take the next dose at the scheduled time.
Dose Modifications For Adverse Reactions
- The recommended dose reduction of Tepmetko for the management of adverse reactions is 225 mg orally once daily.
- Permanently discontinue Tepmetko in patients who are unable to tolerate 225 mg orally once daily.
- The recommended dosage modifications of Tepmetko for adverse reactions are provided in Table 1.
Table 1: Recommended Tepmetko Dosage Modifications for Adverse Reactions
|Adverse Reaction||Severity||Dose Modification|
|Interstitial Lung Disease (ILD) /Pneumonitis||Any grade||Withhold Tepmetko if ILD is suspected. Permanently discontinue Tepmetko if ILD is confirmed.|
|Increased ALT and/or AST without increased total bilirubin||Grade 3||Withhold Tepmetko until recovery to baseline ALT/AST. If recovered to baseline within 7 days, then resume Tepmetko at the same dose; otherwise resume Tepmetko at a reduced dose.|
|Grade 4||Permanently discontinue Tepmetko.|
|Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or hemolysis||ALT and/or AST greater than 3 times ULN with total bilirubin greater than 2 times ULN||Permanently discontinue Tepmetko.|
|Increased total bilirubin without concurrent increased ALT and/or AST||Grade 3||Withhold Tepmetko until recovery to baseline bilirubin. If recovered to baseline within 7 days, then resume Tepmetko at a reduced dose; otherwise permanently discontinue.|
|Grade 4||Permanently discontinue Tepmetko.|
|Other adverse reactions||Grade 2||Maintain dose level. If intolerable, consider withholding Tepmetko until resolved, then resume Tepmetko at a reduced dose.|
|Grade 3||Withhold Tepmetko until resolved, then resume Tepmetko at a reduced dose.|
|Grade 4||Permanently discontinue Tepmetko.|
What drugs interact with Tepmetko?
Effects Of Other Drugs On Tepmetko
Dual Strong CYP3A Inhibitors and P-gp Inhibitors
- The effect of strong CYP3A inhibitors or P-gp inhibitors on Tepmetko has not been studied clinically.
- However, metabolism and in vitro data suggest concomitant use of drugs that are strong CYP3A inhibitors and P-gp inhibitors may increase tepotinib exposure, which may increase the incidence and severity of adverse reactions of Tepmetko.
- Avoid concomitant use of Tepmetko with dual strong CYP3A inhibitors and P-gp inhibitors.
Strong CYP3A Inducers
- The effect of strong CYP3A inducers on Tepmetko has not been studied clinically.
- However, metabolism and in vitro data suggest concomitant use may decrease tepotinib exposure, which may reduce Tepmetko efficacy. Avoid concomitant use of Tepmetko with strong CYP3A inducers.
Effects Of Tepmetko On Other Drugs
Certain P-gp Substrates
- Tepotinib is a P-gp inhibitor. Concomitant use of Tepmetko increases the concentration of P-gp substrates, which may increase the incidence and severity of adverse reactions of these substrates.
- Avoid concomitant use of Tepmetko with certain P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities.
- If concomitant use is unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.
Is Tepmetko safe to use while pregnant or breastfeeding?
- Based on findings in animal studies and the mechanism of action, Tepmetko can cause fetal harm when administered to a pregnant woman.
- There are no available data on the use of Tepmetko in pregnant women.
- There are no data regarding the secretion of tepotinib or its metabolites in human milk or its effects on the breastfed infant or milk production.
- Advise women not to breastfeed during treatment with Tepmetko and for one week after the final dose.
Latest Cancer News
Daily Health News
Multimedia: Slideshows, Images & Quizzes
Lung Cancer: Early Signs, Symptoms, Stages
Learn about lung cancer early warning signs, symptoms and treatments. What causes stage IV lung cancer? Get more information on...
Lung Cancer Risks: Myths and Facts
Learn about lung cancer myths and facts. Explore how cigar smoke, menthol, and pollution can increase your risk of lung cancer...
Lung Cancer Quiz: Signs and Symptoms
Lung cancer is the number one cause of cancer deaths in both men and women in the U.S. and worldwide. Get the facts about lung...
Picture of Lung Cancer
Cancer of the lung, like all cancers, results from an abnormality in the body's basic unit of life, the cell. See a picture of...
Related Disease Conditions
Lung cancer kills more men and women than any other form of cancer. Eight out of 10 lung cancers are due to tobacco smoke. Lung cancers are classified as either small-cell or non-small-cell lung cancers.
What Percentage of Smokers Get Lung Cancer?
According to the Centers for Disease Control and Prevention (CDC), lung cancer develops in around 10 to 20 percent of all smokers. Scientists believe that smoking is responsible for over 80 percent of lung cancers.
What Does Lung Cancer Feel Like When It Starts?
Lung cancer refers to the uncontrolled growth of cells that starts in the lungs. Lung cancer occurs when any of the several cells in the lungs undergo an abnormal change in its genetic code. This change is called a mutation.
What Should I Do After an Unwanted Pregnancy?
There are a variety of options that may help you handle your situation. It might help you to visualize each option and decide how you feel about it. Consider reaching out to trained professionals or close friends if you get overwhelmed.
Small Cell Lung Cancer vs. Non-Small Cell Lung Cancer
Non-small cell lung cancers (NSCLC) consist of large cell carcinomas, adenocarcinomas, and squamous cell carcinomas. Small cell lung cancer (SCLC) usually starts in the bronchi and typically appears in those who smoke. SCLC and NSCLC are staged in different manners, and SCLC tends to metastasize more quickly than NSCLC. Signs and symptoms of NSCLC and SCLC include shortness of breath, coughing up blood, recurring lung infections, and chest pain. Treatment may involve radiation therapy, chemotherapy, and surgery.
How Do You Test Yourself for Lung Cancer?
Lung cancer is the second leading cause of death in the United States. It is hard to detect in the early stages because it does not cause obvious signs and symptoms. Signs and symptoms most often appear when lung cancer has grown deep and extensively inside the lung tissue and/or spread to other organs.
What Are the Four Types of Lung Cancer?
The four types of lung cancer are classified by what kind of cells the cancer affects and what the tumor cells look like under a microscope. Lung cancers can be small-cell or non-small cell, further classified as squamous cell carcinoma or adenocarcinoma.
Can Pancoast Lung Cancer Be Cured?
Pancoast tumors are a rare type of lung cancer that forms at the extreme top of either of the lungs. Due to their location at the top of the lung, there’s a high chance that cancer might attack the adjacent tissue and produce typical symptoms.
Six Early Signs of Lung Cancer
Lung cancer is the third most common cancer in the United States. It may not show its signs and symptoms in its early stages. Signs and symptoms typically appear in the advanced stage of the disease.
Can You Smoke When You Have Lung Cancer?
Continuing to smoke after the diagnosis or during the treatment of lung cancer is usually not recommended because it may decrease the survival rate and even interfere with the treatment process.
What Is the Survival Rate of Non-Small Cell Lung Cancer?
There are two main types of lung cancers, namely, small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for 85% of all lung cancer cases in the United States. It must be noted that medical science is progressing with leaps and bounds, and treatment for lung cancer must be initiated and maintained despite the stage of diagnosis.
What Are The Main Causes Of Lung Cancer?
Lung cancer refers to an uncontrolled growth of cells that starts in the lungs. The cells then cluster together to form a tumor that can spread to other sites in the body. Lung cancer is the third most common cancer in the United States (skin cancer being the first and prostate and breast cancer being the second most common cancer in men and women, respectively).
Where Do You Feel Lung Cancer Pain?
In its early stages, lung cancer typically does not produce any signs and symptoms. However, if it does, you will experience coughing and wheezing that do not go away within three weeks.
How Does Smoking Affect Lung Cancer?
Tobacco smoke is a complex mixture of gaseous and particulate substances, and many of these are potential carcinogens. More than 4000 individual components have been identified in cigarette smoke. Some of these are carcinogens (substances that contribute to the development of cancer), such as benzene and nitrosamines.
What Is Lung Cancer Pain Like?
Lung cancer, also known as lung carcinoma, is defined as an uncontrolled growth of tumor cells in the lungs. The principal role of the lungs is to allow gaseous exchange between the air and blood and facilitate the availability of oxygen for cellular functions.
Treatment & Diagnosis
- Lung Cancer FAQs
- Sensitive to Smoke, Lung Cancer Gene
- Lung Cancer and Chemotherapy
- Lung Cancer Signs and Symptoms
- 5 Causes of Lung Cancer in Non-Smokers
- Dana Reeve Dies of Lung Cancer by Dr. Stoppler
- What Is the Survival Rate for Lung Cancer Nodules?
- Why Does Lung Cancer Spread So Fast?
- Can You Get Lung Cancer After Quitting Smoking?
- Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
- Lung Cancer - Health Beat Audio Segment
Medications & Supplements
Prevention & Wellness
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.